About Cutaneous Lymphoma

Press Releases

06/23/2015 : Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
SGX301 has previously been granted both orphan drug and fast track designations from the US Food and Drug Administration (FDA) for the first-line treatment of CTCL, a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system.
11/17/2014 : Cutaneous Lymphoma Foundation Announces Winners of 2014 CLARIONS Research Grant and Young Investigator Award
CLF Awards Programs advocate for greater research into cutaneous T-cell lymphoma and support young investigators in the field
04/17/2014 : 2014 Young Investigator Award Winner Announced
The CLF announces winner of 2014's Society for Investigative Dermatology (SID) Young Investigator Award (YIA).
12/08/2013 : CLARIONS Research Grant and Young Investigator Award Winners Announced
The CLF announces winners of 2013's CLARIONS Research Award Grants and the 2013 American Society of Hematology Young Investigator Award (YIA).
12/02/2013 : Cutaneous Lymphoma Foundation Announces New President And Welcomes New Members to Board of Directors
The Cutaneous Lymphoma Foundation (CLF) Board of Directors is pleased to welcome Christopher Shipp as its new President and the addition of three new board members.
01/31/2013 : The Cutaneous Lymphoma Foundation Launches Research Awards Program
Prestigious New CLARIONS Grant Program Charts Path to Cure Cutaneous Lymphoma
12/09/2012 : Giorgia Saporiti, MD Receives Young Investigator's Award from the Cutaneous Lymphoma Foundation
Dr. Saporiti Received Prestigious Award During the 2012 American Society of Hematology Meeting
07/17/2012 : Cutaneous Lymphoma Foundation Appoints New CEO
The Board of Directors of the Cutaneous Lymphoma is pleased to welcome Susan Thornton as its new CEO.
06/05/2012 : Ceptaris Secures $10 Million in Series D-1 Financing for Mechlorethamine Gel Production
Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced on June 5, 2012 that it has raised $10 million in Series D-1 financing for the operational expenses of producing mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides. Ceptaris has also received a Complete Response Letter from the FDA regarding the New Drug Application (NDA) for the gel.
01/05/2012 : Yaupon Changes Name to Ceptaris Therapeutics, Inc.
Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today it has changed its name to Ceptaris Therapeutics, Inc., effective immediately. The new name is intended to reflect the recent changes in management and the Company’s ongoing transformation into a commercial organization. Ceptaris Therapeutics’ lead drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell Lymphoma (CTCL).  
Syndicate content